APA (7th ed.) Citation

KE, L., M, J., S, H., S, A., AM, P., X, L., . . . KA, K. (2025). Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas. Frontiers in oncology, 15, 1617087. https://doi.org/10.3389/fonc.2025.1617087

Chicago Style (17th ed.) Citation

KE, Lake, et al. "Single-agent Rituximab and Ultra-low-dose Adaptive Radiotherapy for the Treatment of Indolent B-cell Non-Hodgkin Lymphomas." Frontiers in Oncology 15 (2025): 1617087. https://doi.org/10.3389/fonc.2025.1617087.

MLA (9th ed.) Citation

KE, Lake, et al. "Single-agent Rituximab and Ultra-low-dose Adaptive Radiotherapy for the Treatment of Indolent B-cell Non-Hodgkin Lymphomas." Frontiers in Oncology, vol. 15, 2025, p. 1617087, https://doi.org/10.3389/fonc.2025.1617087.